Molecular Vision 2017; 23:140-148 <>
Received 13 September 2016 | Accepted 16 March 2017 | Published 18 March 2017

A mutagenesis-derived Lrp5 mouse mutant with abnormal retinal vasculature and low bone mineral density

Jeremy R. Charette,1 Sarah E. Earp,2,3 Brent A. Bell,3 Cheryl L. Ackert-Bicknell,1,4 Dana A. Godfrey,4 Sujata Rao,2,3 Bela Anand-Apte,2,3 Patsy M. Nishina,1 Neal S. Peachey2,3,5

1The Jackson Laboratory, Bar Harbor, ME; 2Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; 3Cole Eye Institute, Cleveland Clinic, Cleveland, OH; 4Center for Musculoskeletal Research, Department of Orthopaedics, University of Rochester, Rochester, NY; 5Louis Stokes Cleveland VA Medical Center, Cleveland, OH

Correspondence to: Neal Peachey, Cole Eye Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; Phone: (216) 445-1942; FAX: (216) 636-5046; email:


Purpose: Familial exudative vitreoretinopathy (FEVR) is caused by mutations in the genes encoding low-density lipoprotein receptor-related protein (LRP5) or its interacting partners, namely frizzled class receptor 4 (FZD4) and norrin cystine knot growth factor (NDP). Mouse models for Lrp5, Fzd4, and Ndp have proven to be important for understanding the retinal pathophysiology underlying FEVR and systemic abnormalities related to defective Wnt signaling. Here, we report a new mouse mutant, tvrm111B, which was identified by electroretinogram (ERG) screening of mice generated in the Jackson Laboratory Translational Vision Research Models (TVRM) mutagenesis program.

Methods: ERGs were used to examine outer retinal physiology. The retinal vasculature was examined by in vivo retinal imaging, as well as by histology and immunohistochemistry. The tvrm111B locus was identified by genetic mapping of mice generated in a cross to DBA/2J, and subsequent sequencing analysis. Gene expression was examined by real-time PCR of retinal RNA. Bone mineral density (BMD) was examined by peripheral dual-energy X-ray absorptiometry.

Results: The tvrm111B allele is inherited as an autosomal recessive trait. Genetic mapping of the decreased ERG b-wave phenotype of tvrm111B mice localized the mutation to a region on chromosome 19 that included Lrp5. Sequencing of Lrp5 identified the insertion of a cytosine (c.4724_4725insC), which is predicted to cause a frameshift that disrupts the last three of five conserved PPPSPxS motifs in the cytoplasmic domain of LRP5, culminating in a premature termination. In addition to a reduced ERG b-wave, Lrp5tvrm111B homozygotes have low BMD and abnormal features of the retinal vasculature that have been reported previously in Lrp5 mutant mice, including persistent hyaloid vessels, leakage on fluorescein angiography, and an absence of the deep retinal capillary bed.

Conclusions: The phenotype of the Lrp5tvrm111B mutant includes abnormalities of the retinal vasculature and of BMD. This model may be a useful resource to further our understanding of the biological role of LRP5 and to evaluate experimental therapies for FEVR or other conditions associated with LRP5 dysfunction.


Mutagenesis and analysis of mice by system-specific screens has been used to understand the genes that contribute to a wide range of biological processes and diseases [1]; the use of this approach by multiple laboratories has yielded a rich array of mouse models for biomedical research [2,3]. Structural and functional screens have been used to identify mutants that impact the eye [2,4-8]. Among these, the Translational Vision Research Models (TVRM) program at the Jackson Laboratory develops new mouse models of eye disease by exposing wild-type (WT) C57BL/6J male mice to the mutagen N-ethyl-N-nitrosourea (ENU) and screening the eyes of offspring generated through a three-generation mating strategy by indirect ophthalmoscopy and/or electroretinography [6].

In this report, we describe the generation and initial characterization of a new autosomal recessive model (tvrm111B) caused by a mutation in the low-density lipoprotein receptor-related protein 5 (Lrp5) gene. Affected tvrm111B mice were identified via an electroretinogram (ERG) screen. The abnormal ERG phenotype was used to map the tvrm111B trait to chromosome 19, and further genetic analysis revealed that the phenotype is caused by a single-nucleotide insertion that affects the three terminal PPPSPxS motifs of the protein.

Our studies focused on two aspects of the Lrp5tvrm111B phenotype, namely retinal vasculature and bone density. These factors were chosen based on the recognized role of LRP5 in canonical Wnt signaling and the phenotypes associated with mutations in LRP5/Lrp5 in humans and mice. In humans, inactivating mutations in LRP5 cause osteoporosis pseudoglioma (OPPG) [9,10]. OPPG is an autosomal recessive disorder in which affected patients develop severe juvenile-onset osteoporosis and congenital blindness [9,10]. Other reports have linked LRP5 mutations to familial exudative vitreoretinopathy (FEVR), a retinal condition characterized by abnormal development of the deep retinal capillary beds [11,12], or to high bone mineral density (BMD) [13,14]. Abnormal retinal vascular development has been described in two mutant mouse lines that carry inactivating mutations in Lrp5 due to ENU mutagenesis or gene targeting [5,15]. In addition, Kato et al. [16] noted that Lrp5−/− mice have low bone mass and incomplete regression of the embryonic hyaloid vasculature. As described here, each of these abnormalities is recapitulated in Lrp5tvrm111B, which will be available through The Jackson Laboratory either as mating pairs, if available, or reconstituted from cryopreserved sperm and will provide value for the study of these systems and others that involve LRP5 signaling.


Mice and mapping

All procedures used in animal experiments were approved by the Institutional Animal Care & Use Committees of the institutions involved. Homozygous tvrm111B mice were identified by the TVRM mutagenesis program [6], in which male C57BL/6J mice were administered ENU in weekly injections of 80 mg/kg for 3 weeks [17]. In this program [18], ENU-treated males were mated to WT females to create generation (G) 1 offspring. Male G1 offspring were mated to WT females to generate G2 offspring, which were then mated back to their G1 fathers to generate G3 offspring; the G3 offspring were then examined by ERG [19] to identify mice with abnormal outer retinal function.

To map the tvrm111B locus, affected C57BL/6J mice were crossed to WT DBA/2J mice to generate filial (F) 1 mice that were heterozygous at the tvrm111B locus and carried a C57BL/6J and a DBA/2J allele at each locus. These F1 mice were then intercrossed to generate F2 mapping mice. F2 mice were examined by ERG, after which DNA was prepared from tail biopsies using proteinase K digestion and isopropyl alcohol extraction. DNA samples from 10 affected and 10 unaffected F2 offspring were pooled and subjected to a genome-wide scan in which 48 simple sequence length polymorphic markers that distinguish C57BL/6J and DBA/2J strains were used [20]. Once tvrm111B was localized to chromosome 19 and the linkage was confirmed, a total of 195 samples from tvrm111B F2 progeny were genotyped for markers D19Mit68 and D19Mit109 and single-nucleotide polymorphisms rs30822407 and rs30990604 to refine the map position.

Whole-exome sequencing

Genomic DNA (1 µg) was fragmented using a E220 Focused-ultrasonicator (Covaris, Woburn, MA) E220 to a range of sizes centered on 300 bp. The precapture paired-end library was constructed using the NEBNext DNA Library Prep Master Mix set for Illumina (New England BioLabs, Ipswich, MA) including a bead-based size selection to select for inserts with an average size of 300 bp followed by 18 cycles of PCR. The precapture library was hybridized to the Roche (Madison, WI) NimbleGen SeqCap EZ Mouse Exome Design (Ref #9999042611) capture probe set according to the manufacturer’s instructions. The sequencing library was quantified by quantitative PCR (qPCR), pooled with three similar libraries, and sequenced on a single lane of an Illumina (San Diego, CA) HiSeq 2000 using a 2×100-base (paired-end) sequencing protocol.

Chromosome 19 enrichment and exome sequencing

The precapture library was generated as above and was hybridized to a 1M Agilent Technologies (Santa Clara, CA) SureSelect DNA Capture Array using published hybridization and posthybridization methods [21]. The array was printed with 390,033 (×2) 60-bp probes covering the NCBI build 37 coordinates from chromosome 19 (chr19) bases 3000001 to 6207730 (CM001012.1). The sequencing library was quantified by qPCR and sequenced on an Illumina MiSeq using a 2×100-base (paired-end) sequencing protocol. The resulting sequences were analyzed manually using the Integrative Genomics Viewer (Broad Institute, Cambridge, MA) to identify the cytosine insertion in Lrp5 (c.4724_4725insC).


To confirm the identified mutation, we amplified and sequenced the Lrp5 genomic DNA within the region containing the mutation in both the segregating mapping and the maintenance colonies. PCR products were purified using QIAquick PCR purification according to the manufacturer’s recommendations (QIAGEN, Germantown, MD) and sequenced using BigDye Terminator Cycle Sequencing Chemistry and separated by capillary electrophoresis on Applied Biosystems 3730xl DNA Analyzer.

RNA isolation and quantitative real-time PCR

RNA was isolated from whole-eyes enucleated from P8 animals using an RNeasy Mini kit (QIAGEN). Tissues were homogenized in TRIzol (Thermofisher Scientific, Waltham, MA) and phase separated. An on-column DNase I treatment was performed and RNA was eluted using nuclease-free water. Quantitative real-time reverse transcription PCR (qRT-PCR) was performed with the iTaq Universal SYBR Green SuperMix (Bio-Rad, Hercules, CA) and gene-specific primers [22] using the CFX96 Real-Time PCR Detection System (Bio-Rad). Transcripts were analyzed by the comparative CT method using Actb as a normalizing gene. Error bars represent the additive propagation of error [23]. The primers used to amplify the target genes examined are listed in Table 1.


After overnight dark adaptation, mice were anesthetized with ketamine (80 mg/kg) and xylazine (16 mg/kg) and their pupils were dilated with 1% tropicamide and 2.5% phenylephrine HCl eye drops. ERGs were recorded with a stainless-steel wire contacting the anesthetized (1% proparacaine HCl) corneal surface. This active electrode was referenced to a needle electrode placed in the cheek; a second needle electrode placed in the tail served as ground. Responses were differentially amplified (0.03–1,000 Hz) and stored using an LKC (Gaithersburg, MD) UTAS E-3000 signal averaging system. For examination of F2 progeny, a single stimulus condition was used (1.4 log cd s/m2 flash presented in darkness). To characterize the tvrm111B phenotype, ERGs were recorded under dark-adapted stimulus conditions using flash stimuli that ranged from −3.6 to 1.2 log cd s/m2 and under light-adapted conditions using flash stimuli that ranged from −0.8 to 1.9 log cd s/m2 and were superimposed on a steady 20 cd/m2 rod-desensitizing background field [24].

In vivo retinal imaging

Animal preparation, imaging, and recovery were performed as previously described [25,26]. Fluorescein angiography (FA-SLO) was performed using a Heidelberg Engineering (Franklin, MA) model HRA2 confocal scanning laser ophthalmoscope. Sodium fluorescein (Alcon Fluorescite, Fort Worth, TX) was administered (10–20 mg/kg) via an intraperitoneal injection, and FA-SLO images of the superficial and deep capillary plexus were collected at 1, 2, 3, and 4 min postinjection [27]. Spectral domain optical coherence tomography (SDOCT) was performed using a Bioptigen (Durham, NC) model SDOIS SDOCT system. B-scans of the horizontal and vertical meridians were collected through the optic nerve at 1,000 A-scans/B-scan × 30 frames. B-scan images with dimensions of 0.4 mm (depth) × approximately 1.6 mm (width) were exported to ImageJ and coregistered and averaged using StackReg/TurboReg/Plugins [28].


Enucleated mouse eyes were fixed in 4% paraformaldehyde (PFA) for 30 min and washed with PBS before removal of the anterior segment and lens. PBS is purchased as a 10X powder without calcium and magnesium (Midwest Scientific, Valley Park, MO). It is diluted to 1X (pH = 7.5) with distilled water and contains KCl (2.6 mM), KH2PO4 (1.47 mM), NaCl (137.93 mM) and Na2HPO4 anhydrous (8.09 mM). Whole retinas were removed and permeabilized with 1% Triton X-100 in PBS for 45 min followed by rinsing with PBS. Retinas were incubated with Isolectin GS-IB4 (ThermoFisher Scientific, Waltham, MA; 20 µg/ml) from Griffonia simplicifolia, Alexa Fluor 488 conjugate (ThermoFisher Scientific) for 48 h, washed with PBS, and mounted in Vectashield before visualization with a Leica SP8 confocal microscope (Leica Microsystems, Buffalo Grove, IL) with a 40×/1.30NA objective. Z-stack images were taken through the entire thickness of the whole mount retina and analyzed with three-dimensional (3D) modality and depth coding to visualize the vascular layers using Leica Application Suite software.

Dissection and staining of the hyaloid vessels

P8 pups were perfused with 4% PFA and kept at room temperature for 10 min before enucleation. After fixation and dissection, isolated hyaloid vessels were transferred to a slide and allowed to dry overnight. Hyaloid vessels were washed with PBS and stained with Hoechst 33342 (1:10,000) for 10 min (ThermoFisher), mounted in Fluoro-Gel (Electron Microscopy Sciences, Hatfield, PA), and imaged using a Zeiss AxioVision microscope (Zeiss, Thornwood, NY) and a 5× objective as previously described [29].

BMD measures

Areal BMD (aBMD) and body composition were assessed using peripheral dual-energy X-ray absorptiometry (PIXImus, GE-Lunar, Madison, WI) as previously described [30] in five homozygous Lrp5tvrm111B and five C57BL/6J female mice at 5 months of age. We examined female mice to avoid any gender difference in BMD, noting that the BMD changes associated with LRP5/Lrp5 mutations are not reported to differ between males and females. In short, the scans assessed whole-body (exclusive of the head) bone mineral content (BMC) and bone area. Whole-body aBMD is calculated by dividing BMC by bone area. The short-term coefficient of variation for repeat measures of total body aBMD was 8.3%.


The ERG phenotype in homozygous tvrm111B mice is caused by a nucleotide insertion in Lrp5

As affected tvrm111B mice appear generally normal, we used the ERG phenotype to map the tvrm111B locus. Affected mice were crossed to WT DBA/2J mice, and the resulting F1 mice were intercrossed. Of the 195 F2 progeny that were screened by ERG, 49 (25.1%) had an abnormal ERG. The tvrm111B phenotype was mapped to chromosome 19 using D19Mit68-rs30822407-rs30990604-D19Mit109 markers. The phenotype did not recombine with markers D19Mit68 and rs30822407, but it did recombine with rs30990604, which formed the lower chromosomal boundary for the ERG phenotype. The ERG phenotype mapped between 0 and 6.099 MB on chr19. The critical region included Cabp4 and Lrp5, both of which were considered strong candidate genes due to the ERG phenotype of previously published mutants (Cabp4 [31]; Lrp5 [15].

We used gene expression to further evaluate these two candidate genes. No expression or coding sequence differences of Cabp4 were observed between unaffected littermates and affected tvrm111B mice. A mutation in Lrp5 was identified through SureSelect DNA capture array investigating region chr19: 3,000,001–6,207,730 (NCBI build 37 coordinates) followed by MiSeq sequencing. Probes were created every 4 bp, excluding regions that were masked due to repeats. Approximately 390,000 probes were created in this region, and they were duplicated on the array. The causal variant (Lrp5 c.4724_4725insG) is a single-nucleotide insertion in the final two PPPSPxS motifs at the C-terminal end of the Lrp5 gene. This insertion adds an additional cytosine to a string of nine successive cytosines in a highly conserved guanine–cytosine (GC)-rich region. The single base insertion results in the replacement of 39 C-terminal amino acids by a new 20-amino-acid polypeptide and a premature stop codon. This mutation is identical to an independently derived ENU mutation previously described [5]. Going forward, the new mutant line will be referred to as Lrp5tvrm111B.

Lrp5tvrm111B mice have an abnormal ERG b-wave

Figure 1 compares strobe flash ERGs obtained from control and Lrp5tvrm111B homozygous littermates under stimulus conditions that allow rod- and cone-mediated function to be measured. Under dark-adapted conditions (Figure 1A), both a- and b-wave amplitudes are reduced, with a much greater impact on the b-wave. Under light-adapted conditions (Figure 1B), the overall amplitude of the cone ERG is reduced.

Abnormal retinal blood vessels in Lrp5tvrm111B mice

Together with norrin and frizzled 4, LRP5 is required for development of the deep layers of the retinal vasculature and for regression of the embryonic hyaloid vessels [5,9,15,16,23,32-35]. We conducted a series of analyses to examine these features in Lrp5tvrm111B mice. We first used fluorescein angiography to determine whether Lrp5tvrm111B retinal vessels were patent. While fluorescein did not leak from control vessels (Figure 2A, top), leakage, as indicated by the increasing background signal within the avascular space, was clearly noted in Lrp5tvrm111B mice (Figure 2A, bottom). In addition, a deep vascular plexus was not visible in Lrp5tvrm111B mice, although this plexus could be easily discerned in the controls (not shown). When we used SDOCT to examine the cross-sectional morphology, we noted that the retinal vasculature in the Lrp5tvrm111B mice appeared to terminate (Figure 2B, white arrows) in the inner nuclear layer (Figure 2B, black arrows), which also suggested the lack of a deep vascular plexus. To examine this further, we stained whole mount retinas with 488-Fluor-conjugated isolectin to label the retinal vasculature. As shown in Figure 2C, the deep retinal layer was poorly developed in Lrp5tvrm111B retinas in comparison to controls. When examined at P8, the hyaloid vessels persisted in Lrp5tvrm111B retinas beyond what was observed in the control retina (Figure 2D); they also persisted in adult mutants (data not shown).


Lrp5tvrm111B mice exhibit a significant decrease in whole body aBMD (Figure 3A). This results from a decrease in bone mineral content (Figure 3B), and not from a change in skeletal size (not shown). A trend toward a decrease in lumbar spinal BMD in Lrp5tvrm111B mutant mice relative to controls was noted; however, this was not statistically significant (control=0.0657 versus Lrp5tvrm111B=0.0594 g/cm2, p=0.18).

Analysis of Wnt-pathway-mediated genes

To understand the impact of the Lrp5 mutation on Wnt signaling, we used qRT-PCR to examine expression of a series of Wnt-related genes [21]. These studies were conducted at P8, when retinal vascular development was active. Interestingly, Lrp5 expression was significantly elevated in Lrp5tvrm111B mutants relative to the WT (Figure 4), suggesting that a decrease in activity resulted in upregulation of Lrp5 mRNA levels. As shown in Figure 4, we also noted that several other genes were significantly upregulated (Plvap, Wnt10b) or downregulated (Cldn5, Mfsd2, Slc38a5) in the Lrp5tvrm111B retina.


In this report, we describe an autosomal recessive mouse for Lrp5. The Lrp5tvrm111B was generated in a mutagenesis program that utilizes eye-specific outcome measures to identify potential mutants involving the retina [6]. The Lrp5tvrm111B mutant was originally identified based on an abnormal ERG b-wave, a feature that was used to map the genetic location. The mutation involves the insertion of an additional cytosine in a GC-rich region. While we were not able to determine whether this additional nucleotide occurs at the start, middle, or end of a repeat of nine cytosines, the net result is a mutation that is identical to that obtained from an independent ENU mutagenesis screen by Xia and coworkers [5], suggesting that this region is highly mutable. The observed increase in transcript expression of the mutant allele of Lrp5 is probably due to regulatory feedback mechanisms that exist under normal conditions and have been observed for other mutations, such as the homozygous rd5 mutation in tubby (tubrd5) allele [36].

Our studies indicate that the Lrp5tvrm111B model shares multiple phenotypic features with previously developed Lrp5 mutants [5,15,16]. These include defects in vascular development, such as the persistence of the hyaloid vasculature into adulthood, and incomplete growth of the deep inner retinal capillary bed. These changes are shared by mutants for Fzd4 and Norrin, which control the vascular developmental processes along with LRP5 [33,35]. The incomplete development of the inner retinal blood supply is thought to underlie the abnormal ERG b-wave observed in Lrp5 mutants, and mutants for Fzd4 and Norrin [37].

Another feature of the Lrp5tvrm111B phenotype is low BMD. Given the role of Lrp5 in osteoblastogenesis, the reduction in bone mass in Lrp5−/− mice, associated with a decrease in bone formation and a decrease in osteoblast number, is not surprising [16]. This phenotype is reminiscent of the phenotype of OPPG patients homozygous for inactivating mutations of LRP5 [10]. The phenotype of the Lrp5tvrm111B mutant is less profound than that of the complete loss of function allele for Lrp5, but given the low–bone mass phenotypes observed in our mice, it is consistent with the hypothesis that this mutation results in a decrease in Lrp5/β-catenin-Wnt signaling in the osteoblast.

The Lrp5tvrm111B was developed in a program devoted to the generation of new research mouse models. While the focus of the program is the identification of mutants affecting the eye, once established, these models are available to the research community. The Lrp5tvrm111B mutant will be available for researchers interested in studying the role of LRP5 in the retinal vasculature, bone development, or other systems.


We are grateful to Doug Howell for running the initial ERG screens associated with this project and to Gwen Sturgill-Short for technical assistance. Grant Support: This research was supported by grants from the USA National Institutes of Health (R01EY016501 and R01EY11996 to PMN; P30CA34196 The Jackson Laboratory Cancer Center Core Grant; R01EY016490, R01EY020861 and R01EY026181 to BA-A and R01EY027077 to SR), Knights Templar Eye Foundation (KTEF1401SR) and Research to Prevent Blindness (RBP1503SR), the USA Veterans Administration Medical Research Service, a Foundation Fighting Blindness Center Grant to the Cole Eye Institute, Cleveland Clinic, an unrestricted award from Research to Prevent Blindness to the Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine, The Wolf Family Foundation, and the Llura and Gordon Gund Foundation.


  1. Takahashi JS, Pinto LH, Vitaterna MH. Forward and reverse genetic approaches to behavior in the mouse. Science. 1994; 264:1724-33. [PMID: 8209253]
  2. Pinto LH, Vitaterna MH, Siepka SM, Shimomura K, Lumayag S, Baker M, Fenner D, Mullins RF, Sheffield VC, Stone EM, Heffron E, Takahashi JS. Results from screening over 9000 mutation-bearing mice for defects in the electroretinogram and appearance of the fundus. Vision Res. 2004; 44:3335-45. [PMID: 15536001]
  3. Wang T, Zhan X, Bu CH, Lyon S, Pratt D, Hildebrand S, Choi JH, Zhang Z, Zeng M, Wang KW, Turer E, Chen Z, Zhang D, Yue T, Wang Y, Shi H, Wang J, Sun L, SoRelle J, McAlpine W, Hutchins N, Zhan X, Fina M, Gobert R, Quan J, Kreutzer M, Arnett S, Hawkins K, Leach A, Tate C, Daniel C, Reyna C, Prince L, Davis S, Purrington J, Bearden R, Weatherly J, White D, Russell J, Sun Q, Tang M, Li X, Scott L, Moresco EM, McInerney GM, Karlsson Hedestam GB, Xie Y, Beutler B. Real-time resolution of point mutations that cause phenovariance in mice. Proc Natl Acad Sci USA. 2015; 112:E440-9. [PMID: 25605905]
  4. Jablonski MM, Dalke C, Wang X, Lu L, Manly KF, Pretsch W, Favor J, Pardue MT, Rinchik EM, Williams RW, Goldowitz D, Graw J. An ENU-induced mutation in Rs1h causes disruption of retinal structure and function. Mol Vis. 2005; 11:569-81. [PMID: 16088326]
  5. Xia C-H, Liu H, Cheung D, Wang M, Cheng C, Du X, Chang B, Beutler B, Gong X. A model for familial exudative vitreoretinopathy caused by LRP5 mutations. Hum Mol Genet. 2008; 17:1605-12. [PMID: 18263894]
  6. Won J, Shi LY, Hicks W, Wang J, Hurd R, Naggert JK, Chang B, Nishina PM. Mouse model resources for vision research. J Ophthalmol. 2011; 2011:391384 [PMID: 21052544]
  7. Won J, Shi LY, Hicks W, Wang J, Naggert JK, Nishina PM. Translational vision research models program. Adv Exp Med Biol. 2012; 723:391-7. [PMID: 22183357]
  8. Charette JR, Samuels IS, Yu M, Stone L, Hicks W, Shi LY, Krebs MP, Naggert JK, Nishina PM, Peachey NS. A chemical mutagenesis screen identifies mouse models with ERG defects. Adv Exp Med Biol. 2016; 854:177-83. [PMID: 26427409]
  9. Gong Y, Slee RB, Fukai N, Rawaki G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Jüppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML, Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001; 107:513-23. [PMID: 11719191]
  10. Levasseur R, Lacombe D, de Vernejoul MC. LRP5 mutations in osteoperosos-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine. 2005; 72:207-14. [PMID: 15850991]
  11. Toomes C, Bottomley HM, Jackson RM, Towns KV, Scott S, Mackey DA, Craig JE, Jiang L, Yang Z, Trembath R, Woodruff G, Gregory-Evans CY, Gregory-Evans K, Parker MJ, Black GC, Downey LM, Zhang K, Inglehearn CF. Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am J Hum Genet. 2004; 74:721-30. [PMID: 15024691]
  12. Jiao X, Ventruto V, Trese MT, Shastry BS, Hejtmancik JF. Autosomal recessive familial exudative vitreoretinopathy is associated with mutations in LRP5. Am J Hum Genet. 2004; 75:878-84. [PMID: 15346351]
  13. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002; 346:1513-21. [PMID: 12015390]
  14. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002; 70:11-9. [PMID: 11741193]
  15. Xia C-H, Yablonka-Reuveni Z, Gong X. LRP5 is required for vascular development in deeper layers of the retina. PLoS One. 2010; 5:e11676 [PMID: 20652025]
  16. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA, , 2nd Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol. 2002; 157:303-14. [PMID: 11956231]
  17. Justice MJ, Carpenter DA, Favor J, Neuhauser-Klaus A, Hrabé de Angelis M, Soewarto D, Moser A, Cordes S, Miller D, Chapman V, Weber JS, Rinchik EM, Hunsicker PR, Russell WL, Bode VC. Effects of ENU dosage on mouse strains. Mamm Genome. 2000; 11:484-8. [PMID: 10886010]
  18. Herron BJ, Lu W, Rao C, Liu S, Peters H, Bronson RT, Justice MJ, McDonald JD, Beier DR. Efficient generation and mapping of recessive developmental mutations using ENU mutagenesis. Nat Genet. 2002; 30:185-9. [PMID: 11818962]
  19. Hawes NL, Chang B, Hageman GS, Nusinowitz S, Nishina PM, Schneider BS, Smith RS, Roderick TH, Davisson MT, Heckenlively JR. Retinal degeneration 6 (rd6): A new mouse model for human retinitis punctata albescens. Invest Ophthalmol Vis Sci. 2000; 41:3149-57. [PMID: 10967077]
  20. Taylor BA, Navin A, Phillips SJ. PCR-amplification of simple sequence repeat variants from pooled DNA samples for rapidly mapping new mutations of the mouse. Genomics. 1994; 21:626-32. [PMID: 7959741]
  21. Hodges E, Rooks M, Xuan Z, Bhattacharjee A, Benjamin Gordon D, Brizuela L, Richard McCombie W, Hannon GJ. Hybrid selection of discrete genomic intervals on custom-designed microarrays for massively parallel sequencing. Nat Protoc. 2009; 4:960-74. [PMID: 19478811]
  22. Chen J, Stahl A, Krah NM, Seaward MR, Joyal J-S, Juan AM, Hatton CJ, Aderman CM, Dennison RJ, Willett KL, Sapieha P, Smith LEH. Retinal expression of Wnt-pathway mediated gene in low-density lipoprotein receptor-related protein 5 (lrp5) knockout mice. PLoS One. 2012; 7:e30203 [PMID: 22272305]
  23. Nordgård O, Kvaløy JT, Farmen RK, Heikkilä R. Error propagation in relative real-time reverse transcription polymerase chain reaction quantification models: the balance between accuracy and precision. Anal Biochem. 2006; 356:182-93. [PMID: 16899212]
  24. Peachey NS, Pearring JN, Bojang P, , Jr Hirschtritt ME, Sturgill-Short GM, Ray TA, Furukawa T, Koike C, Goldberg AFX, Shen Y, McCall MA, Nawy S, Nishina PM, Gregg RG. Depolarizing bipolar cell dysfunction due to a Trpm1 point mutation. J Neurophysiol. 2012; 108:2442-51. [PMID: 22896717]
  25. Bell BA, Kaul C, Hollyfield JG. A protective eye shield for prevention of media opacities during small animal ocular imaging. Exp Eye Res. 2014; 127:280-7. [PMID: 25245081]
  26. Bell BA, Kaul C, Bonilha VL, Rayborn ME, Shadrach K, Hollyfield JG. The BALB/c mouse: Effect of standard vivarium lighting on retinal pathology during aging. Exp Eye Res. 2015; 135:192-205. [PMID: 25895728]
  27. Paques M, Simonutti M, Roux MJ, Picaud S, Levavasseur E, Bellman C, Sahel JA. High resolution fundus imaging by confocal scanning laser ophthalmoscopy in the mouse. Vision Res. 2006; 46:1336-45. [PMID: 16289196]
  28. Thévenaz P, Ruttimann UE, Unser M. A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Process. 1998; 7:27-41. [PMID: 18267377]
  29. Rao S, Lobov IB, Vallance JE, Tsujikawa K, Shiojima I, Akunuru S, Walsh K, Benjamin LE, Lang RA. Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch. Development. 2007; 134:4449-58. [PMID: 18039971]
  30. Ackert-Bicknell CL, Shockley KR, Horton LG, Lecka-Czernik B, Churchill GA, Rosen CJ. Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I. Endocrinology. 2009; 150:1330-40. [PMID: 18948404]
  31. Haeseleer F, Imanishi Y, Maeda T, Possin DE, Maeda A, Lee A, Rieke F, Palczewski K. Essential role of Ca2+-binding protein 4, a Cav1.4 channel regulator, in photoreceptor synaptic function. Nat Neurosci. 2004; 7:1079-87. [PMID: 15452577]
  32. Richter M, Gottanka J, May CA, Welge-Lüssen U, Berger W, Lutjen-Drecoll E. Retinal vasculature changes in Norrie disease mice. Invest Ophthalmol Vis Sci. 1998; 39:2450-7. [PMID: 9804153]
  33. Xu Q, Wang Y, Dabdoub A, Smallwood PM, Williams J, Woods C, Kelley MW, Jiang L, Tasman W, Zhang K, Nathans J. Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell. 2004; 116:883-95. [PMID: 15035989]
  34. Luhmann UF, Lin J, Acar N, Lammel S, Feil S, Grimm C, Seeliger MW, Hammes HP, Berger W. Role of the Norrie disease pseudoglioma gene in sprouting angiogenesis during development of the retinal vasculature. Invest Ophthalmol Vis Sci. 2005; 46:3372-82. [PMID: 16123442]
  35. Ye X, Wang Y, Cahill H, Yu M, Badea TC, Smallwood PM, Peachey NS, Nathans J. Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization. Cell. 2009; 139:285-98. [PMID: 19837032]
  36. Noben-Trauth K, Naggert JK, North MA, Nishina PM. A candidate gene for the mouse mutation tubby. Nature. 1996; 380:534-8. [PMID: 8606774]
  37. Pardue MT, Peachey NS. Mouse b-wave mutants. Doc Ophthalmol. 2014; 128:77-89. [PMID: 24395437]